Don't Fret Delays in Treating Colon Cancer, Study Suggests
WEDNESDAY, Nov. 15, 2017 -- Delays in colon cancer treatment may not increase the risk of death, according to a new study.
Canadian researchers examined data from more than 900 people diagnosed with stage 1 to stage 3 colon cancer. Some began treatment within a month of diagnosis, and others started treatment either 30 to 59 days, 60 to 89 days, 90 to 119 days or more than four months after diagnosis.
The average time between diagnosis and the start of treatment was 38 days.
Delaying treatment had no effect on overall survival or on people remaining cancer-free, the researchers said.
The study appears in the December issue of the journal Diseases of the Colon and Rectum.
The researchers hope their findings "will result in discussion regarding the appropriateness of the existing recommendations regarding optimal wait time to surgery targets," said study author Dr. Kerollos Wanis, from Western University in Ontario.
"We also hope that our study will assuage provider and patient anxiety regarding surgical treatment delay, particularly when additional preoperative work-up and optimization is required," Wanis said in a journal news release.
© 2020 HealthDay. All rights reserved.
Posted: November 2017
Read this next
MONDAY, Oct. 19, 2020 -- Early diagnosis of colon cancer is crucial to improve a patient's chance of survival, an expert says. Colon cancer is on the rise, especially among...
FRIDAY, Oct. 16, 2020 -- Many Americans who get recommended colon cancer screening may end up with "surprise" medical bills, a new study suggests. Looking at insurance claims for...
WEDNESDAY, Sept. 30, 2020 -- Certain nutrients, foods and medicines may help protect you against colon cancer, a large research review suggests. A team of international...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.